Lidocaine Fresenius Kabi

Lidocaine Hydrochloride Monohydrate, the active ingredient in Lidocaine Fresenius Kabi, is a local anesthetic presented as a sterile injectable solution for epidural, intramuscular and intravenous use. It provides rapid onset nerve block for minor surgical procedures, epidural analgesia, and ventricular arrhythmia control in adult patients and can be administered by trained healthcare professionals.

GNH USA supplies Lidocaine Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide and clinics across multiple continents with reliable cold‑chain logistics where required.

Lidocaine is used in several clinical settings that require rapid, reversible nerve blockade.

- Minor surgical procedures: provides local anesthesia to numb the operative area. - Epidural analgesia: delivers analgesia for labor, postoperative pain, or chronic pain management. - Ventricular arrhythmias: used intravenously to suppress abnormal cardiac electrical activity.

Lidocaine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Tingling or numbness at the injection site. - Metallic taste. - Dizziness. - Mild hypotension.

Serious or Rare Side Effects: - Seizures. - Severe cardiac arrhythmias (e.g., ventricular tachycardia). - Allergic reactions including anaphylaxis.

When using lidocaine, several safety considerations should be observed.

- Cardiac assessment: evaluate baseline ECG and heart function before use. - Hepatic impairment: reduce dose or monitor closely in patients with liver disease. - Allergy history: avoid in individuals with known lidocaine or amide‑type anesthetic hypersensitivity. - Elderly patients: use lower initial doses due to decreased clearance. - Concomitant CNS depressants: monitor for enhanced sedation or respiratory depression. - Store at room temperature: keep in original container, protect from light and moisture.

Lidocaine interacts with several drug classes; awareness of major and moderate interactions helps prevent adverse events.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): additive cardiac toxicity. - Beta‑blockers (e.g., propranolol): risk of severe bradycardia and hypotension. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase lidocaine plasma levels.

Moderate Interactions (Monitor Closely): - Other local anesthetics: cumulative nerve toxicity. - Diuretics (e.g., furosemide): may enhance lidocaine’s effect on cardiac conduction. - Calcium channel blockers (e.g., verapamil): may potentiate hypotensive effects.